Rockwell Medical Inc
NASDAQ:RMTI

Watchlist Manager
Rockwell Medical Inc Logo
Rockwell Medical Inc
NASDAQ:RMTI
Watchlist
Price: 2.25 USD 2.27% Market Closed
Market Cap: 68.2m USD
Have any thoughts about
Rockwell Medical Inc?
Write Note

Rockwell Medical Inc
Income from Continuing Operations

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Rockwell Medical Inc
Income from Continuing Operations Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Income from Continuing Operations CAGR 3Y CAGR 5Y CAGR 10Y
Rockwell Medical Inc
NASDAQ:RMTI
Income from Continuing Operations
-$1.2m
CAGR 3-Years
66%
CAGR 5-Years
49%
CAGR 10-Years
25%
Haemonetics Corp
NYSE:HAE
Income from Continuing Operations
$123.8m
CAGR 3-Years
58%
CAGR 5-Years
13%
CAGR 10-Years
15%
ICU Medical Inc
NASDAQ:ICUI
Income from Continuing Operations
-$111m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Align Technology Inc
NASDAQ:ALGN
Income from Continuing Operations
$441.6m
CAGR 3-Years
-16%
CAGR 5-Years
1%
CAGR 10-Years
12%
Lantheus Holdings Inc
NASDAQ:LNTH
Income from Continuing Operations
$427.6m
CAGR 3-Years
N/A
CAGR 5-Years
65%
CAGR 10-Years
N/A
Merit Medical Systems Inc
NASDAQ:MMSI
Income from Continuing Operations
$120m
CAGR 3-Years
40%
CAGR 5-Years
40%
CAGR 10-Years
19%
No Stocks Found

Rockwell Medical Inc
Glance View

Market Cap
72.7m USD
Industry
Health Care

Rockwell Medical, Inc. is a biopharmaceutical company, which engages in the development of treatment for anemia, kidney disease, iron deficiency, and hemodialysis. The company is headquartered in Wixom, Michigan and currently employs 300 full-time employees. The firm is developing and commercializing its technology platform, Ferric Pyrophosphate Citrate (FPC) for the transformative treatments for iron deficiency in multiple disease states. The company is also a supplier of hemodialysis concentrate products to kidney dialysis clinics. The firm has developed therapies namely Triferic and Triferic AVNU from its FPC platform. The Company’s products from its FPC platform, Triferic (dialysate) and Triferic AVNU intravenous (IV), is a therapy indicated to replace iron and maintain hemoglobin in adult hemodialysis patients. Its Triferic AVNU, is an IV formulation of Triferic, for use by hemodialysis patients. its dialysis concentrates products include CitraPure Citric Acid Concentrate, Dri-Sate Dry Acid Concentrate, RenalPure Liquid Acid Concentrate, Dry Acid Concentrate Mixer, RenalPure and SteriLyte Bicarbonate Concentrate and Ancillary products.

RMTI Intrinsic Value
1.83 USD
Overvaluation 19%
Intrinsic Value
Price

See Also

What is Rockwell Medical Inc's Income from Continuing Operations?
Income from Continuing Operations
-1.2m USD

Based on the financial report for Sep 30, 2024, Rockwell Medical Inc's Income from Continuing Operations amounts to -1.2m USD.

What is Rockwell Medical Inc's Income from Continuing Operations growth rate?
Income from Continuing Operations CAGR 10Y
25%

Over the last year, the Income from Continuing Operations growth was 87%. The average annual Income from Continuing Operations growth rates for Rockwell Medical Inc have been 66% over the past three years , 49% over the past five years , and 25% over the past ten years .

Back to Top